Ou SH - Search Results

1

"ACHILLES" Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834).

Luo FX, Ou SI. Luo FX, et al. Lung Cancer (Auckl). 2024 May 18;15:69-73. doi: 10.2147/LCTT.S461758. eCollection 2024. Lung Cancer (Auckl). 2024. PMID: 38784059 Free PMC article.

2

MARIPOSA-2: Is the treatment worse than the disease?

Lee ATM, Ou SI. Lee ATM, et al. Med. 2024 May 18:S2666-6340(24)00209-5. doi: 10.1016/j.medj.2024.05.005. Online ahead of print. Med. 2024. PMID: 38763142 No abstract available.

3

A pragmatic guide for management of adverse events associated with lorlatinib.

Liu G, Mazieres J, Stratmann J, Ou SI, Mok T, Grizzard M, Goto Y, Felip E, Solomon BJ, Bauer TM. Liu G, et al. Lung Cancer. 2024 May;191:107535. doi: 10.1016/j.lungcan.2024.107535. Epub 2024 Mar 15. Lung Cancer. 2024. PMID: 38554546 Free article. Review.

4

Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.

Chen LN, Lee ATM, Nagasaka M, Ou SI. Chen LN, et al. J Thorac Oncol. 2024 Mar;19(3):380-384. doi: 10.1016/j.jtho.2023.12.018. J Thorac Oncol. 2024. PMID: 38453326 No abstract available.

5

Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.

Lee ATM, Ou SI. Lee ATM, et al. Lung Cancer (Auckl). 2024 Feb 27;15:19-27. doi: 10.2147/LCTT.S446878. eCollection 2024. Lung Cancer (Auckl). 2024. PMID: 38433979 Free PMC article.

6

MARIPOSA-2: Is the treatment worse than the disease?

Lee ATM, Ou SI. Lee ATM, et al. Med. 2024 Feb 9;5(2):115-117. doi: 10.1016/j.medj.2023.12.010. Med. 2024. PMID: 38340706

7

Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data.

Nagasaka M, Brazel D, Ou SI. Nagasaka M, et al. Expert Opin Investig Drugs. 2024 Feb;33(2):79-84. doi: 10.1080/13543784.2024.2305131. Epub 2024 Jan 29. Expert Opin Investig Drugs. 2024. PMID: 38224083 Review.

8

Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.

Ou SI, Prawitz T, Lin HM, Hong JL, Tan M, Proskorovsky I, Hernandez L, Jin S, Zhang P, Lin J, Patel J, Nguyen D, Neal JW. Ou SI, et al. Clin Lung Cancer. 2024 May;25(3):e145-e152.e3. doi: 10.1016/j.cllc.2023.11.011. Epub 2023 Dec 4. Clin Lung Cancer. 2024. PMID: 38114357 Clinical Trial.

9

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.

Chen J, Bearz A, Kim DW, Mamdani H, Bauman J, Chiari R, Ou SI, Solomon BJ, Soo RA, Felip E, Shaw AT, Thurm H, Clancy JS, Lee K, O'Gorman M, Tanski C, Pithavala YK. Chen J, et al. Clin Pharmacokinet. 2024 Feb;63(2):171-182. doi: 10.1007/s40262-023-01309-4. Epub 2023 Dec 11. Clin Pharmacokinet. 2024. PMID: 38079095 Free PMC article.

10

Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).

Ou SI, Hagopian GG, Zhang SS, Nagasaka M. Ou SI, et al. J Thorac Oncol. 2024 May;19(5):706-718. doi: 10.1016/j.jtho.2023.12.008. Epub 2023 Dec 7. J Thorac Oncol. 2024. PMID: 38070596 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

361 results

Search Page